| Previous close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 165.00 |
| Expiry date | 2023-10-20 |
| Day's range | 0.0600 - 0.0600 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley Fool$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
I favor holding onto these players for the long term to truly benefit from their earnings potential.
Motley FoolWith New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal.
Motley Fool2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Two candidates with loads of potential are Moderna (NASDAQ: MRNA) and Teladoc Health (NYSE: TDOC). Moderna's earnings soared over the past two years thanks to its blockbuster COVID-19 vaccine. Moderna has set out a plan that could result in $30 billion in sales down the road, which surpasses its peak of about $18 billion in coronavirus vaccine sales.
